Driehaus Capital Management Adds $10M in Edgewise Therapeutics, Inc. ($EWTX)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Driehaus Capital Management increased its position in Edgewise Therapeutics, Inc. ($EWTX) by 6.84% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,477,942 shares of Edgewise Therapeutics, Inc. after buying 286,749 shares during the quarter. Driehaus Capital Management's holdings in Edgewise Therapeutics, Inc. were worth $155.97 million as of its most recent filing.
Edgewise Therapeutics, Inc. Stock Down 18.5%
Shares of Edgewise Therapeutics, Inc. ($EWTX) traded around $34.83 on Saturday, down 18.5% for the day.
Edgewise Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Get Edgewise Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EWTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.